Article Figures & Data
Figures
- FIG 1.
PRISMA flow chart.
- FIG 2.
Risk of bias and applicability concerns by QUADAS-2 domain.
Tables
- Table 1:
Pooled analyses for CTP and subparameters for detection of vasospasm and delayed cerebral ischemia
Studies Pooled Sensitivity (%) (95% CI) Pooled Specificity (%) (95% CI) Positive LR Negative LR Diagnostic OR Vasospasm CTP 11 85.6 (74.2–92.5) 87.9 (79.2–93.3) 7.10 (3.87–13.04) 0.16 (0.09–0.31) 43.41 (14.4–130.49) CBF 5 60.9 (45.0–74.7) 92.2 (80.7–97.1) 7.83 (3.06–20.06) 0.42 (0.29–0.62) 18.47 (6.16–55.38) DCI CTP 22 82.1 (74.5–87.8) 79.6 (73.0–84.9) 4.01 (2.94–5.47) 0.23 (0.12–0.33) 17.79 (9.66–32.76) CBF 12 73.5 (62.0–82.4) 84.1 (77.1–89.3) 4.62 (3.12–6.84) 0.31 (0.32–0.47) 14.64 (7.58–28.25) CBV 7 64.3 (50.6–75.9) 73.9 (60.1–84.1) 2.46 (1.72–3.52) 0.48 (0.37–0.64) 5.08 (3.16–8.17) MTT 12 80.7 (73.3–86.5) 69.3 (61.4–76.2) 2.63 (2.04–3.39) 0.28 (0.20–0.40) 9.46 (5.49–16.29) TTP 7 82.2 (71.4–89.5) 70.6 (59.2–79.9) 2.79 (1.91–4.09) 0.25 (0.15–0.43) 11.06 (4.85–25.20) Tmax 4 63.8 (52.5–73.8) 81.5 (72.5–88.1) 3.45 (2.44–4.88) 0.44 (0.34–0.57) 7.77 (5.00–12.09) - Table 2:
Pooled subgroup analysis and metaregression for CTP for detection of delayed cerebral ischemia
Studies Pooled Sensitivity (%) Pooled Specificity (%) Positive LR Negative LR Diagnostic OR (95% CI) (95% CI) CTP <72 hr 5 55.8 (27.3–80.8) 93.7 (66.8–99.1) 8.81 (1.12–68.38) 0.47 (0.23–0.96) 18.0.66 (1.45–239.63) CTP >72 hr 5 84.5 (57.3–95.7) 84.9 (48.0–97.2) 5.60 (1.14–27.60) 0.18 (0.05–0.65) 30.73 (2.50–378.08) Relative sensitivity >72 hr vs <72 hr = 1.52 (95% CI, 0.85–2.68); P = .11; relative specificity >72 hr vs <72 hr = 0.91 (95% CI, 0.67–1.22); P = .47 MTT threshold 5 75.4 (61.6–85.4) 66.6 (51.3–79.0) 2.25 (1.33–3.81) 0.37 (0.20–0.69) 6.10 (1.98–18.78) MTT qualitative 5 67.9 (56.9–85.9) 78.8 (69.2–85.9) 3.19 (2.09–4.89) 0.41 (0.29–0.57) 7.86 (3.92–15.76) Relative sensitivity threshold vs qualitative = 1.14 (95% CI, 0.92–1.40); P = .24; relative specificity threshold vs qualitative = 0.82 (95% CI, 0.66–1.02); P = .10 CBF 7 74.1 (60.8–84.1) 87.4 (75.1–94.2) 5.91 (2.99–11.67) 0.30 (0.20–0.45) 19.96 (8.99–44.32) CBV 7 64.3 (50.6–75.9) 73.9 (60.1–84.1) 2.45 (1.72–3.52) 0.48 (0.37–0.64) 5.08 (3.16–8.17) Relative sensitivity CBV vs CBF = 0.88 (95% CI, 0.69–1.12); P = .30; relative specificity CBV vs CBF = 0.86 (95% CI, 0.70–1.05); P = .13 CBF 8 78.9 (72.7–84.0) 79.6 (64.7–89.3) 3.87 (2.11–7.10) 0.27 (0.19–0.36) 14.62 (6.38–33.49) MTT 8 81.5 (73.5–87.5) 79.2 (69.9–86.2) 3.91 (2.68–5.71) 0.23 (0.16–0.34) 16.77 (9.31–30.22) Relative sensitivity MTT vs CBF =1.03 (95% CI, 0.93–1.14); P = .64; relative specificity MTT vs CBF = 1.02 (0.85–1.23); P = .85 CBV 6 70.6 (63.0–77.2) 68.5 (59.9–75.9) 2.24 (1.72–2.91) 0.43 (0.33–0.56) 5.21 (3.24–8.40) MTT 6 84.3 (76.9–89.7) 74.4 (66.7–80.9) 3.30 (2.43–4.47) 0.21 (0.14–0.33) 15.64 (8.03–30.46) Relative sensitivity MTT vs CBV = 1.182 (95% CI, 1.05–1.33); P = .009; relative specificity MTT vs CBV = 1.09 (95% CI, 0.94–1.25); P = .27
